Exorbitant pain and suffering awards in medical malpractice lawsuits, also known as non-economic damages, have been blamed for numerous evils, including high physician insurance rates in some states and increases in health care costs due to “defensive medicine” practices.
Extended lymph node dissection (LND) does not significantly change overall disease recurrence and survival patterns in patients who undergo radical cystectomy for bladder cancer compared with limited LND, but certain patient subgroups experience improvements in these outcomes, a study found.
Incidental detection of renal cell carcinoma (RCC) is increasing and is associated with better survival from the malignancy, according to a population-based study conducted in Iceland.
Denosumab can delay bone metastases in men with castration-resistant prostate cancer (CRPC), a study found.
PHILADELPHIA—High dietary salt intake may decrease the risk of chronic kidney disease (CKD) and low dietary potassium intake may increase the risk, investigators reported at Kidney Week 2011.
PHILADELPHIA—Ferumoxytol has an efficacy comparable to iron sucrose in treating iron deficiency anemia in patients with chronic kidney disease (CKD), but is associated with lower adverse event (AE) rates, according to the findings a head-to-head comparison of the two formulations presented at Kidney Week 2011.
PHILADELPHIA—Among kidney transplant recipients with focal segmental glomerulosclerosis (FSGS), African-Americans (AA) have a greater prevalence of risk factors for allograft failure compared with other races, according to findings presented at Kidney Week 2011.
PHILADELPHIA—Live kidney donation by African-Americans increases their risk of hypertension, researchers reported at Kidney Week 2011.
PHILADELPHIA—Baseline plasma phosphate level is an important risk factor for cardiovascular events and mortality in hemodialysis (HD) patients, investigators reported at Kidney Week 2011.
PHILADELPHIA—Patients with chronic kidney disease (CKD) who have a low response to erythropoiesis-stimulating agents (ESAs) are at increased risk of progressing to end-stage renal disease (ESRD), investigators reported at Kidney Week 2011.
